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The completion of the Human Genome Project provided a reference sequence to which researchers could
compare sequences from individual patients in the hope of identifying disease-causing mutations. However,
this still necessitated candidate gene testing or a very limited screen of multiple genes using Sanger
sequencing. With the advent of high-throughput Sanger sequencing, it became possible to screen hundreds
of patients for alterations in hundreds of genes. This process was time consuming and limited to a few
locations/institutions that had the space to house tens of sequencing equipment. The development of next
generation sequencing revolutionized the process. It is now feasible to sequence the entire exome of multiple
individuals in about 10 days. However, this meant that a massive amount of data needed to be filtered to
identify the relevant alteration. This is presently the rate-limiting step in providing a convincing association
between a genetic alteration and a human disorder.
© 2013 The Authors. Published by Elsevier Ltd.Open access under CC BY-NC-ND license.The Human Genome Project was completed over
a decade ago in 2001 after a 10-year effort involving
multiple laboratories. The Human Genome Project
provided a valuable resource, a sequence for the
human genome that could serve as a “reference” to
which patient sequences could be compared as
means to identify “variants”. As anticipated, this
ability quickly led to the identification of novel genes
being associated with numerous human disorders.
However, the progress was limited to “candidate
gene” testing. This meant that first, one either had to
have localized a particular disease to a restricted
localization in the human genome by means of
linkage analysis or had to utilize a patient with a
syndrome and a balanced chromosomal transloca-
tion that disrupted the function of a gene. Thus,
progress in identifying genes associated with human
diseases proceeded rather slowly, one syndrome at
a time.
The rate of progress increased somewhat over the
following 5 years or so, as laboratories began to
employ other technologies. First, as chromosome
arrays, a cytogenetic test that allowed detection of
deletions at the 200kb level, became more wide-
spread, it became clear that some copy numberuthors. Published by Elsevier Ltd. Open access uvariants were associated with various syndromes.
The further refinement of the platform from DNA
probes to oligonucleotide probes allowed for the
detection of even smaller deletions/duplications in
the genome. It also became possible, with lower
costs, to screen relatively large numbers of patients
with a broad phenotype such as intellectual disabil-
ity, autism spectrum disorders, and various neuro-
developmental conditions. By doing so, one was no
longer limited to studying small cohorts of patients
with specific rare human disorders. Therefore,
multiple candidate regions and genes were being
identified as being associated with human disorders.
The downside was that the detected deletions/
duplications created problems for geneticists. First,
one did not know how to handle duplications—how
would one be able to show or prove that too much of
a gene product was pathogenic. Additionally, per-
haps the breakpoints at the fringes of duplication
affected the level of transcription of genes on either
side of the breakpoint. Second, the deletions, in most
instances, involved multiple genes. Third, the delet-
ed/duplicated region may include regulatory ele-
ments and, thus, copy number variants can affect the
expression of genes outside the involved region. TheJ. Mol. Biol. (2013) 425, 3914–3918nder CC BY-NC-ND license.
3915Perspective: Detecting Genetic Alterationssituation was similar to the linkage situation in which
multiple candidate genes existed in a discrete
region. However, unlike the linkage situation where
sequence analysis could provide strong evidence
that an alteration detected in a candidate genes was
likely the relevant pathogenic change for the patient,
one had to rely on other approaches such as
conducting a screen of a cohort of patients with a
similar phenotype in the hope of identifying loss of
function mutations in one of the presumptive genes.
As the microarray or oligoarray technology was
being applied to cohorts of patients with various
conditions, sequence technology had progressed
enough to allow for large resequencing projects to be
undertaken. These were usually initiated by in-
stitutions or centers that had the capacity to run
tens of sequencing machines simultaneously, there-
by conducting high-throughput, Sanger-based rese-
quencing for targeted genomic regions or for a large
number of genes. Thus, it became possible to
sequence hundreds of genes in hundreds of patients
with a similar presentation, such as intellectual
disability, autism spectrum disorders, or complex
conditions, thereby quickly identifying potential
pathogenic changes in multiple genes. An advan-
tage to this approach was the possibility of identify-
ing multiple mutations in a single gene, thereby
rather quickly identifying a novel gene associated
with a human disease. The downside was that many
more missense alterations would be found in various
novel genes and that these would be of unknown
significance without further analysis.
The follow-up analysis of missense alterations
was aided by the development of numerous bioin-
formatic software packages that attempted to predict
the pathogenicity of an amino acid substitution.
These packages utilize different approaches. Some
will predict the consequence of the substitution on
peptide stability. Some will use biochemical infor-
mation integrated with an analysis of the conserva-
tion of the residue involved. Lastly, as it is now
apparent that innocuous amino acid substitutions
adversely alter splicing, packages accessing theTable 1. Bioinformatic protein prediction sites
Software
iPTree http://210.60.98.19/IPT
I-Mutant http://folding.uib.es/i-m
MuPro http://www.ics.uci.edu/
MuStab http://bioinfo.ggc.org/m
Panther http://www.pantherdb.o
PMut http://mmb2.pcb.ub.es
PolyPhen http://genetics.bwh.har
SIFT http://blocks.fhcrc.org/
Rescue-ESE http://genes.mit.edu/bu
Splice Site Calculator http://192.168.50.223/s
Splice Site Score Calculation http://lai.cshl.edu/new_
Mutation Taster http://www.mutationtaspossible interference of a variant with the splicing
process have been developed (Table 1).
There are four main online software packages that
focus on predicting the effect of a mutation on
peptide stability, either over a short range (iPTree-S-
TAB) or over the entire protein (I-Mutant, MuPro,
MuStab).
iPTree-STAB uses information over seven resi-
dues, three residues on either side of the mutation
site and the mutation site itself, and implements a
decision tree coupled with an adaptive boosting
algorithm and a regression tree for the prediction of
protein stability. I-Mutant is a support vector machine
(SVM)-based Web server that predicts protein
stability calculated using ΔΔG due to a single
mutation using an algorithm trained on a data set
derived from ProTherm and either protein structure
or protein sequence. MuPro is another package that
utilizes SVMs to predict protein stability changes for
a single amino acid mutation in two different contexts
based on structure-dependent and sequence-de-
pendent information. MuStab employs 20 protein
sequence features without the structural information
and SVMs to predict the effect on protein stability
due to the mutation.
Another class of software packages predicts the
possible damaging or pathogenic effect of a mis-
sense mutation based on the alteration in the
conservation of a sequence. These include Poly-
Phen-2, Panther, PMut, and SIFT.
Panther is a curated database of protein families,
trees, and subfamilies, which attempts to provide a
representation of evolutionary events in a gene
family. Using this evolutionary information, a predic-
tion of deleterious substitutions is made by calculat-
ing the probability of a deleterious event based on
the HMM (Hidden Markov Model) profile at the
specific site in the protein. However, the program
may not provide a probability score if there is limited
information on a particular protein's family or if all the
isoforms for a given gene transcript are not
considered. This means that the package can be of
limited value for some proteins.Website Focus
REEr/iptree.htm Protein stability
utant/i-mutant2.0.html Protein stability
~baldig/mutation.html Protein stability
ustab/ Protein stability
rg/ Conservation
:8080/PMut/ Conservation
vard.edu/pph2/index.shtm Conservation
sift/SIFT_BLink_submit.html Conservation
rgelab/rescue-ese/ Splicing
plicing/maxent.cgi Splicing
alt_exon_db2/HTML/score.html Splicing
ter.org/ Multiple
Table 2. Gene prioritization tools
Tool Publication Website
Suspects Adie et al. [1] www.genetics.med.ed.ac.uk/suspects/
Endeavour Aerts et al. [2] http://www.esat.kuleuven.be/endeavour
ToppGene Chen et al. [3] http://toppgene.cchmc.org/
Candid Hutz et al. [4] https://dsgweb.wustl.edu/hutz/candid.html
GeneWanderer Kohler et al. [5] http://compbio.charite.de/genewanderer/GeneWanderer
GeneDistiller Seelow et al. [6] http://www.genedistiller.org/
Posmed Yoshida et al. [7] http://omicspace.riken.jp/
Pinta Nitsch et al. [8] http://www.esat.kuleuven.be/pinta
Modified from Bornigen et al. [9].
3916 Perspective: Detecting Genetic AlterationsPMut predicts the adverse affect of a single amino
acid mutation by using artificial neural networks
trained with a large database of human disease-as-
sociated mutations and neutral mutations. The
report from PMut can be in three formats: as text
files with a yes/no answer, as bidimensional plots of
the mutation profiles, or as a graph in which each
position in the protein is plotted according to each
pathological index.
PolyPhen-2 uses an iterative algorithm to select
eight sequence-based and three structure-based
predictive features for prediction and calculates a
naive Bayes posterior probability that a given
mutation is damaging and reports estimates of
false positive and true positive rates. Thus, its
utilization of multiple predictive features makes it a
very useful software package. A mutation is also
appraised qualitatively, as benign, possibly damag-
ing, or probably damaging.
The premise of SIFT is that important positions in a
protein sequence have been conserved throughout
evolution, and therefore, substitutions at these
positions may affect protein function. It predicts the
effects of all possible substitutions at each position in
the protein sequence, and a substitution is deemed
deleterious if the scaled probability lies below a
certain threshold value.
Three packages have been developed to consider
the potential for a mutation, particularly a “neutral”
base change, to create or destroy a splice site
(Splice Site Calculator and Splice Site Score
Calculation) or create or destroy an exon splicing
enhancer site (Rescue-ESE).
The Rescue-ESE prediction of an exon splicing
enhancer is obtained from the results of a statistical
analysis of both exon–intron boundaries and splice
site composition. The software package is a hybrid
computational/experimental method that identified
clusters of similar sequences with a statistically
significant enrichment of enhancers, and represen-
tatives of these candidate enhancer motifs were
tested for ESE activity in a splicing reporter
construct. The process identified 238 hexamers as
candidate ESEs, and a sequence is compared to
these candidates to identify the presence of possibleESEs. The Splice Site Calculator accomplishes its
prediction by scoring candidate sites according to
the maximum entropy method, taking into account
the consensus sequences of donor and acceptor
splice sites. The package utilizes a greedy-search
strategy to rank constraints at the resolution of
paired nucleotides at specific positions. Another
splice site package, Splice Site Score Calculation,
employs a 3′ splice site consensus sequence of 13
bases and a 5′ splice site consensus sequence of 9
bases to determine how good a match there is with
the sequence in question. The output value is
compared to mean scores for constitutive exons.
One package can address multiple situations.
Mutation Taster integrates information from multiple
bioinformatic tools and various biomedical data-
bases (such as dbSNP, ClinVar, and a public version
of the Human Gene Mutation Database). The
resulting data of evolutionary conservation, splice
site changes, loss of protein features, and changes
that might affect the amount of mRNA are subse-
quently processed by a naive Bayes classifier that
predicts the outcome of the mutation. As a result, it
represents a rather complete analysis package.
However, a note of caution is needed. It may rule
out a potentially pathogenic alteration because it
exists in a SNP (single nucleotide polymorphism)
database without accounting for the rarity of the
alteration. Also, for 1000 genomes, there is a
threshold of 4 calls before it is listed. It is quite
possible that an extremely rare SNP is pathogenic
even if it exists in a SNP database of variants. Lastly,
Mutation Taster is able to handle insertion deletions
of less than 12 base pairs, mutation creating a
premature stop exon, alterations spanning an
intron–exon boundary, and some non-exonic
alterations.
All of these tools have been invaluable and
provided a tremendous improvement over the
rudimentary analysis that just considered the degree
of conservation of the altered change in an amino
acid (polar versus acidic, for example) or the effect
on simple secondary structures such as a helix or
β-sheet. However, since each package utilizes
different parameters, it is quite important that one
3917Perspective: Detecting Genetic Alterationsemploy multiple packages to be confident that a
change is relevant.
Unfortunately for geneticists, sequencing technol-
ogy did not stand still. It evolved very quickly over the
past 5 years such that a human genome, particularly
the human exome, could be sequenced within 10
days for a few thousand dollars. This next generation
sequencing (NGS) allowed one to expand beyond
focused resequencing of selective regions of the
genome and to sequence all coding regions (whole
exome sequencing) in a single individual. However,
in doing so, NGS also magnified the difficulties of the
evaluation of the variations detected in a patient's
genome. Large data sets are generated by NGS,
and there are thousands of novel alterations
detected in each individual. How to willow down
this immense data set into a manageable number of
candidate gene alterations became of extreme
importance.
Because of this fundamental problem of how to
make sense of the relatively large number of
candidate gene changes associated with a human
phenotype, there was a need to generate computa-
tion algorithms to evaluate these changes and to
prioritize them. Such programs would identify the
most promising candidate gene changes thereby
maximizing the utilization of validation experiments
and functional studies.
During the past few years, multiple gene prioriti-
zation program tools have been developed and
made available via the Web (Table 2). These are
invaluable as one sorts through the many potential
candidate genes generated by whole exome rese-
quencing. The best tools use multiple data sources
and algorithms to prioritize the candidates utilizing
input of the patient's phenotype.
The core of the prioritization tools are various data
sources. Each source takes a different view of the
protein product of a gene. Some utilize complex
biological interactions and pathway databases (Reac-
tome [10], Cytoscape [11], or KEGG [12]). Others
utilize the principle of protein–protein interaction
networks (HPRD [13], STRING [14], or MINT [15]).
Once one has generated the list of candidate gene
changes (those that are novel) using standard
filtering approaches, one applies one or more of the
prioritization tools in Table 2 to generate a prioritized
list of given changes. It needs to be noted that all of
these tools require that one provide a list of seed
genes or keywords so that the prioritization tools can
be “trained” to identify genes relevant to the
phenotype of the patient. The seed genes are pulled
from the literature and can be in pathways previously
associated with the phenotype or interact with pro-
teins known to be associated with the phenotype.
Usually, more than one tool is employed for the
analysis since each tool utilizes different data
sources with different “weights” assigned. Addition-
ally, this approach allows a comparison of multipleprioritized lists and gene changes consistently highly
ranked can be considered worthy of further follow-up.
Once a relatively short list of genes is generated,
then the specific alteration within each gene is
evaluated using the packages listed in Table 1.
Again, it is best if multiple packages are employed in
the analysis as each package has its own advan-
tages and disadvantages. Those changes that are
deemed pathogenic by multiple analyses can then
be pursued using functional studies (in vitro or in
vivo). One must always validate any bioinformatic
prediction by going back into the laboratory and
conducting molecular, biochemical, or animal model
assays.Conclusion
This paper has attempted to provide a short
overview of the tremendous progress that has
been made in identifying novel changes in the
human genome and associating them with human
disorders. It should be noted that no longer is it
difficult for a gene hunter to find a gene but it is
certainly difficult to prove it is relevant to a particular
patient's phenotype. NGS has proved invaluable for
reducing the time to gene identification, but the
amount of data generated has clearly made it
daunting to sift through all the data to arrive at the
proper gene association. Fortunately, bioinformatics
has kept rather good pace with analyzing the data
output. In fact, some groups are now providing
guidance for researchers in selecting the most useful
methods for their projects. One such website† has
been established to assist one in keeping up with the
ever changing bioinformatic software and gene
prioritization tools. In the end, though, no matter
how good the computational tools are, any prediction
needs to be validated at the bench. Unfortunately,
this step is not trivial.Acknowledgements
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